Uncategorized Archives - Page 16 of 137

WednesdayMay 01, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting

Long-term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 exhibited significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p < 0.05) Significantly enhanced clinical outcomes were associated with long-term daily oral CNM-Au8(R) 30 mg treatment (change from original baseline; p < 0.05) Long-term administration of CNM-Au8, spanning up to three years, was well-tolerated, with no significant safety concerns identified This marks the first Phase 2 clinical trial in MS utilizing a non-immunomodulatory drug to achieve a clinical outcome demonstrating improved function supporting remyelination and reparative effects Clene (NASDAQ: CLNN), along with its…

MondayApr 29, 2024 11:15 am

Astiva Health Inc. Innovative Holistic Approach Underscores Understanding That Effective Primary Care Is Foundational

PCPs play pivotal role in successful healthcare approach Evidence shows that primary care helps prevent illness and death Astiva Health has established a healthcare ecosystem where best PCPs are rewarded for expertise, commitment The importance of primary care in a successful healthcare approach has been clearly shown through decades of research. Astiva Health is dedicated to enhancing the quality of medical care through a strong doctor-patient relationship with the success of its model hinging on knowledgeable, competent, and hard-working primary care physicians (“PCPs”) who play a pivotal role in the healthcare system. “Evidence of the health-promoting influence of primary care has been…

MondayApr 29, 2024 9:00 am

HealthLynked Corp. (HLYK) Is ‘One to Watch’

HealthLynked Corp. is a pioneering healthcare technology company revolutionizing patient care through innovative digital solutions Dr. Michael T. Dent, CEO and Chairman, leads the company with a significant history of successful healthcare management and technology development; his prior leadership at NeoGenomics Laboratories, a company with a current market cap of approximately $2 billion, underscores his ability to scale healthcare solutions in competitive markets HealthLynked’s recently launched HealthLynked Network is a state-of-the-art, cloud-based platform designed to significantly improve the efficiency and quality of patient care by enabling a seamless exchange of medical information The leadership’s deep involvement and commitment are reflected…

WednesdayApr 24, 2024 12:00 pm

“Urgent Action: PaxMedica Inc. (NASDAQ: PXMD) Addresses Medical Crisis in Malawi”

In recent developments, PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, has taken swift action to address a pressing medical situation unfolding in Malawi, East Africa. The Ministry of Health (“MOH”) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping sickness crisis affecting the region. PaxMedica swiftly responded to this call for help by committing to provide emergency access to its recently completed registration batches of PAX-101, an IV form of suramin. This decision underscores PaxMedica's dedication to mitigating the devastating impact of sleeping sickness…

TuesdayApr 23, 2024 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse Deterrent Tech Addressing Fentanyl Epidemic

Fentanyl is a potent opioid that is associated with a significant risk of abuse and overdose, contributing to a major drug crisis in the United States Fentanyl has legitimate medical uses in managing severe and chronic pain in medical settings such as hospitals and surgical procedures NTRB is advancing its AVERSA(TM) technology that incorporates aversive agents to prevent abuse, diversion, misuse, and accidental exposure to opioids and other drugs with abuse potential NTRB was recently granted a patent for AVERSA(TM), strengthening its intellectual property portfolio in the United States and globally across 45 countries Fentanyl, a potent opioid, poses a…

MondayApr 22, 2024 10:30 am

Clene Inc. (NASDAQ: CLNN) Continues Development of Lead Drug Candidate CNM Au8(R) for Neurodegenerative Diseases including Parkinson’s Disease

CNM-Au8 is an oral suspension with demonstrated activity in restoring neuronal health and function by increasing energy production and utilization Treatment with CNM-Au8 investigated in clinical trials adjunctive to standard-of-care exhibits no known drug interactions, and aims to enhance function and survival Nearly 90,000 people are diagnosed with Parkinson's disease every year with no approved drug to slow or halt disease progression currently available The Parkinson's disease treatment market was valued at $4.61 billion in 2022 and is expected to reach $11.98 billion by 2030 In recognition of April as Parkinson’s Disease Awareness Month, IBN is highlighting Clene (NASDAQ: CLNN),…

TuesdayApr 16, 2024 9:45 am

Astiva Health Inc. Committed to Creating Healthcare Model Focused on Collaboration Between Physician and Patient

Duke reports that physician-patient relationships can have profound positive and negative implications on clinical care” The dynamic between a physician and patient can be impacted by the ability to speak articulately, including the knowledge of a foreign language, and racial and cultural differences Astiva Health specializes in innovative health plans tailored to meet the unique requirements of its members Astiva Health has a network of providers that closely matches patients’ demographic background, interest, language and culture. This does not come by luck. Astiva has always been working on improving its provider network and physician-patient assignment, ensuring health plans align with client…

WednesdayApr 10, 2024 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients AVERSA technology can be incorporated into any transdermal patch The company has a broad intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico and Australia Nutriband announced in March 2024 that it will submit a New Drug Application to the FDA seeking approval to market AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch In April 2024, the company announced it had received a contract manufacturing order from…

TuesdayApr 09, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug

Clinical trials of Clene’s lead candidate CNM-Au8(R) have shown notable success in crossing the blood-brain barrier and enhancing the brain's bioenergetic metabolites, essentially "reversing the clock" on what would be considered healthy aging CNM-Au8 has shown promise in clinical trials for both ALS and MS, including improvements in survival rates and clinical function Clene was recently featured in an interview of CEO Rob Etherington on ‘First in Human’ podcast In a significant advancement for the treatment of neurodegenerative diseases, Clene (NASDAQ: CLNN) has innovated CNM-Au8, an oral nanotherapeutic designed to revitalize the brain's mitochondrial function. The potential of this drug…

FridayApr 05, 2024 10:30 am

Astiva Health Inc. — Bridging Healthcare Gaps with Proactive, Culturally Responsive Solutions

A Brookings Institution report indicates significant racial disparities in access to health coverage and in health outcomes Astiva Health is focused on reshaping the landscape of personalized and comprehensive healthcare The company carefully considers needs of its members, creates plans that feature cultural strategies for diverse ethnic groups In a world where racial disparities still run rampant in many ways, including health coverage and outcomes, Astiva Health is focused on meeting the healthcare needs of underserved populations. The company recognizes the diverse challenges within key communities and strives to bridge healthcare gaps through proactive and culturally responsive solutions. “In the…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Clene Inc. (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting

Astiva Health Inc. Innovative Holistic Approach Underscores Understanding That Effective Primary Care Is Foundational

HealthLynked Corp. (HLYK) Is ‘One to Watch’

“Urgent Action: PaxMedica Inc. (NASDAQ: PXMD) Addresses Medical Crisis in Malawi”

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse Deterrent Tech Addressing Fentanyl Epidemic

Clene Inc. (NASDAQ: CLNN) Continues Development of Lead Drug Candidate CNM Au8(R) for Neurodegenerative Diseases including Parkinson’s Disease

Astiva Health Inc. Committed to Creating Healthcare Model Focused on Collaboration Between Physician and Patient

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Clene Inc. (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug

Astiva Health Inc. — Bridging Healthcare Gaps with Proactive, Culturally Responsive Solutions

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search